
This fitness stock is a buy as sales momentum is set to continue, Stifel says
Growth in Planet Fitness is nowhere near done, according to Stifel. Analyst Chris O'Cull upgraded shares of the gym chain to buy from hold and raised his price target to $120 from $82. That new objective suggest shares of Planet Fitness could jump roughly 15% from their latest close. The stock has rallied 10% this month after the company reaffirmed its full-year earnings per share, revenue and system-wide same club sales growth. "Recent results suggest gross joins have stabilized, and we believe there are several potential catalysts to keep comparable sales in the mid-to-high single-digit range over the next couple of years," O'Cull said. "The company has improved its marketing efforts, but we believe there is considerable runway for further improvement," O'Cull continued, referring to advertising campaigns he has found encouraging given their messaging that emphasizes Planet Fitness' value as an affordable and nonjudgmental gym. PLNT 1Y mountain Planet Fitness stock performance. According to O'Cull, Planet Fitness locations could see steady improvement in net new unit growth over the next few years given strong top-line performance and ongoing efforts to reduce investment costs. Fueling its strong growth potential is the company's ability to the pricing of its Black Card monthly membership plan from $24.99 to $29.99 later this year, the analyst noted. Planet Fitness also has "promising avenues" to improve the overall value proposition of its Black Card Spa, by expanding potential upgrades to locations' spa areas with the availability of spray tanning, red light therapy and cryotherapy services. "We believe tests to upgrade the Black Card Spa are yielding positive results and could provide new reasons to join. Relative to other consumer-facing segments, Planet's low-cost membership model should also prove relatively resilient in the event of a downturn in consumer spending," O'Cull said. O'Cull also pointed out that efforts to include gym membership costs under individuals' Health Savings Accounts could drive memberships for the fitness industry, potentially benefitting Planet Fitness.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
NewAmsterdam Pharma Company N.V. (NAMS) Initiated with a Buy at Stifel
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) is one of the 13 Biotech Stocks with Huge Upside Potential. It is now under Stifel's coverage, with a buy rating and a $44 price target. A scientist in a lab coat standing in a research lab examining biopharmaceuticals. According to the firm, NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) is a distinct late-stage cardiovascular company with a short-term trajectory toward regulatory filings. Its core asset, obicetrapib, has the potential to differentiate itself in the growing lipid-lowering market, according to Stifel. The analyst points out that obicetrapib potentially differs from earlier attempts in the CETP inhibitor market due to the company's cardiovascular outcomes trial, PREVAIL. Stifel anticipates significant upside even under cautious commercial assumptions. The CETP inhibitor obicetrapib, which is being developed by NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), is intended to decrease cholesterol in the treatment of cardiovascular disease. Stifel cites the PREVAIL study and an extensive amount of supporting data to show that obicetrapib differs significantly from previous CETP failures. New Amsterdam has a legitimate route to market access due to this distinction and impending regulatory milestones. Stifel's $44 price estimate shows that they are confident in the drug's clinical uniqueness and market potential. While we acknowledge the potential of NAMS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 hours ago
- Yahoo
NewAmsterdam Pharma Company N.V. (NAMS) Initiated with a Buy at Stifel
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) is one of the 13 Biotech Stocks with Huge Upside Potential. It is now under Stifel's coverage, with a buy rating and a $44 price target. A scientist in a lab coat standing in a research lab examining biopharmaceuticals. According to the firm, NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) is a distinct late-stage cardiovascular company with a short-term trajectory toward regulatory filings. Its core asset, obicetrapib, has the potential to differentiate itself in the growing lipid-lowering market, according to Stifel. The analyst points out that obicetrapib potentially differs from earlier attempts in the CETP inhibitor market due to the company's cardiovascular outcomes trial, PREVAIL. Stifel anticipates significant upside even under cautious commercial assumptions. The CETP inhibitor obicetrapib, which is being developed by NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), is intended to decrease cholesterol in the treatment of cardiovascular disease. Stifel cites the PREVAIL study and an extensive amount of supporting data to show that obicetrapib differs significantly from previous CETP failures. New Amsterdam has a legitimate route to market access due to this distinction and impending regulatory milestones. Stifel's $44 price estimate shows that they are confident in the drug's clinical uniqueness and market potential. While we acknowledge the potential of NAMS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 hours ago
- Yahoo
Stifel Announces Victor Nesi to Retire as Co-President and Head of Institutional Group; Joins Board of Directors
ST. LOUIS, June 11, 2025 (GLOBE NEWSWIRE) -- Stifel Financial Corp. (NYSE: SF) today announced that Victor Nesi, Co-President and Head of the Institutional Group, will retire from his day-to-day operating responsibilities effective July 1, 2025, after 16 years of distinguished service. Mr. Nesi will, however, continue to serve the firm, simultaneously joining its Board of Directors. 'Victor has been instrumental in building the platform we have today,' said Ronald J. Kruszewski, Chairman and CEO of Stifel. 'The transformation of our Institutional Group under his guidance is one of the great success stories in our firm's history. His strategic vision, leadership, and relentless focus on client service elevated Stifel into a major player in the investment banking world. On a personal level, I am grateful for Victor's partnership and steady counsel, and I am thrilled he will continue to contribute as a valued member of our Board.' Mr. Nesi joined Stifel in 2009, at a formative moment for the firm's Institutional Group. Under his stewardship, the Institutional Group's overall revenue grew from $391 million in 2008 to a peak of $2.2 billion in 2021, while extending its reach across geographies, products, and capabilities. Investment banking revenue alone climbed 20x during this time from $84 million to a record $1.6 billion. In 2024, the Institutional Group reported $1.6 billion in revenue, which represents a more than fourfold increase since Mr. Nesi's arrival. 'Importantly, Victor has also ensured that the Institutional Group is well-positioned for continued success,' added Mr. Kruszewski. 'He has put in place a seasoned leadership team and a strong organizational structure designed to carry forward the culture that he helped establish.' 'It has been an honor and privilege to help grow Stifel into a premier full-service investment bank,' said Mr. Nesi. 'Our success is a direct reflection of the extraordinary people of Stifel – their talent, relentless drive, and unwavering commitment have made everything possible. Together, we have built something enduring with the momentum to achieve even greater things. Consequently, I believe this is the appropriate time for me to step back and allow the next generation of leaders to continue driving our firm forward. I am still energized and eager for new challenges and I look forward to supporting Stifel's continued success in my new role on the Board.' Mr. Nesi's career in investment banking spans four decades. Before coming to Stifel, he held several leadership positions at Merrill Lynch, including Head of Americas Investment Banking. He has also worked as an investment banker at Salomon Brothers and Goldman Sachs and practiced corporate and securities law at Shea & Gould. Stifel Company InformationStifel Financial Corp. (NYSE: SF) is a financial services holding company headquartered in St. Louis, Missouri, that conducts its banking, securities, and financial services business through several wholly owned subsidiaries. Stifel's broker-dealer clients are served in the United States through Stifel, Nicolaus & Company, Incorporated, including its Eaton Partners business division; Keefe, Bruyette & Woods, Inc.; Miller Buckfire & Co., LLC; and Stifel Independent Advisors, LLC. The Company's broker-dealer affiliates provide securities brokerage, investment banking, trading, investment advisory, and related financial services to individual investors, professional money managers, businesses, and municipalities. Stifel Bank and Stifel Bank & Trust offer a full range of consumer and commercial lending solutions. Stifel Trust Company, N.A. and Stifel Trust Company Delaware, N.A. offer trust and related services. To learn more about Stifel, please visit the Company's website at For global disclosures, please visit Media ContactNeil Shapiro, +1 (212) 271-3447shapiron@ Investor Relations Contact Joel Jeffrey, +1 (212) 271-3610 investorrelations@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data